Small molecule-based targeting of chromatin regulatory factors has emerged as a promising therapeutic strategy in recent years. The development and ongoing clinical evaluation of novel agents targeting a range of chromatin regulatory processes, including DNA or histone modifiers, histone readers, and chromatin regulatory protein complexes, has inspired the field to identify and act upon the full compendium of therapeutic opportunities. Emerging studies highlight the frequent involvement of altered mammalian Switch/Sucrose-Nonfermentable (mSWI/SNF) chromatin-remodeling complexes (also called BAF complexes) in both human cancer and neurological disorders, suggesting new mechanisms and accompanying routes toward therapeutic intervention. Here, we review current approaches for direct targeting of mSWI/SNF complex structure and function and discuss settings in which aberrant mSWI/SNF biology is implicated in oncology and other diseases.

近年来，基于小分子的染色质调节因子靶向已成为一种有前途的治疗策略。针对一系列染色质调节过程的新型药物的开发和临床评估，包括DNA或组蛋白修饰剂，组蛋白阅读器和染色质调节蛋白复合物，已经激发了该领域的发现并采取了一系列治疗机会。新兴的研究强调了改变的哺乳动物Switch /蔗糖-不可发酵（mSWI / SNF）染色质重塑复合物（也称为BAF复合物）在人类癌症和神经系统疾病中的频繁参与，提示了新的机制和随之而来的治疗干预途径。这里，